As soon as 48 hours,* NEMLUVIO relieves itch fast, with skin healing that lasts in AD1,2

Fast Itch Relief1
See how NEMLUVIO® provided fast and lasting itch relief1

Lasting Skin Healing2
Discover how NEMLUVIO helped most patients with AD achieve lasting skin clearance2

Favorable Safety Profile3
NEMLUVIO was well tolerated, has no boxed warning, and requires no preliminary lab evaluations or ongoing lab monitoring3
The ARCADIA Trials Reflect Topical Use in AD Clinical Practice2-6
To capture the reality of many with AD, the ARCADIA trials only included those who failed with topical treatment2-6
Experiencing a new reality
See how Whitney relieved her unrelenting itch and achieved lasting skin healing with NEMLUVIO
At that moment, it was the worst that my skin's ever been. I was itchy. I felt this like constant flush, like I was on fire every day. My skin was always red, inflamed, flaky. It was painful.
There were days where my hands were cracked so much that I couldn't even do my job, and others would have to kind of pick up the slack. So that way, you know, things still got done.
I couldn't go out and hang out with my kids to go do things because my skin hurts so bad. I just wanted to be still. Even when you're still, it still hurts.
There's lots of different older treatments, like bleach baths and wet wrapping, light therapy, allergy testing with that includes, you know, getting shots or doing drops and that just took so much time out of my life.
Since starting the NEMLUVIO, I'm not itchy. I would definitely say that my disease was managed with NEMLUVIO at 4 weeks, I've noticed significant improvement in my skin areas of like around my eyes and my hands that were just terrible before and now they're like feeling refreshed.
The skin is healed, and it's not painful. It's important to know that there's other things out there, that there's people that want to help you.
Sign up now for more information about NEMLUVIO for AD
PP-NRS response defined as a ≥4-point improvement from baseline. Data from Phase 3 clinical study (ARCADIA 1) post hoc descriptive analysis of daily PP-NRS improvement; consistent results seen in ARCADIA 2. Significant improvement was achieved at 48 hours (9% with NEMLUVIO + TCS/TCI vs 3% with placebo + TCS/TCI, P≤0.001).1,2
AD=atopic dermatitis; PP-NRS=Peak Pruritus Numerical Rating Scale; TCSI=topical calcineurin inhibitor; TCS=topical corticosteroid.
References: 1. Galderma Laboratories, L.P.; data on file. 2. Galderma Laboratories, L.P.; data on file. Clinical Study Report RD.06.SIR.118163 [ARCADIA LTE]; October 2023. 3. NEMLUVIO (nemolizumab-ilto) injection 30 mg Prescribing Information. Dallas, TX: Galderma Laboratories, L.P. 4. Galderma Laboratories, L.P.; data on file. Clinical Study Report RD.06.SRE.118161 [ARCADIA 1]; September 2023. 5. Misery L, Brenaut E, Pierre O, et al. Chronic itch: emerging treatments following new research concepts. Br J Pharmacol. 2021;178(24):4775-4791. doi:10.1111/bph.15672 6. Orfali RL, Aoki V. Blockage of the IL-31 pathway as a potential target therapy for atopic dermatitis. Pharmaceutics. 2023;15(2):577. doi:10.3390/pharmaceutics15020577